These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10715949)

  • 1. [Problem of drug-resistant tuberculosis and the way of its solution].
    Pukhlik BM
    Probl Tuberk; 1999; (6):17-20. PubMed ID: 10715949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience with rifabutin in the treatment of mycobacterial infections.
    De Cian W; Sassella D; Wynne BA
    Scand J Infect Dis Suppl; 1995; 98():22-6. PubMed ID: 8867175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug sensitivity in Mycobacterium tuberculosis versus its viability, cytotoxicity, genotype, and the course of the process in patients with pulmonary tuberculosis].
    Manicheva OA; Lasunskaia EB; Zhuravlev VIu; Otten TF; Barnaulov AO; Mokrousov IV; Pavlova MV; Vishnevskiĭ BI; Narvskaia OV
    Probl Tuberk Bolezn Legk; 2008; (12):18-22. PubMed ID: 19230183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of bacteriology in the treatment of tuberculosis; the Hungarian program].
    Fodor T
    Orv Hetil; 2000 Sep; 141(36):1981-3. PubMed ID: 11031835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan.
    Lee CN; Lin TP; Chang MF; Jimenez MV; Dolfi L; Olliaro P
    J Chemother; 1996 Apr; 8(2):137-43. PubMed ID: 8708745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An update on the antibiotic therapy of tuberculosis].
    Rossi G
    Recenti Prog Med; 1999 May; 90(5):241-3. PubMed ID: 10380549
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of mycobacterial infections in HIV-negative immunocompromised patients.
    Heurlin N
    Scand J Infect Dis Suppl; 1995; 98():21. PubMed ID: 8867174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status and perspectives on the development of rifamycin derivative antibiotics].
    Hidaka T
    Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Characterization of the drug resistance spectrum of rifampicin-resistant M. tuberculosis to other first-line antituberculous drugs].
    Isakova ZhT; Goncharova ZK; Aldashev AA
    Probl Tuberk Bolezn Legk; 2008; (11):39-42. PubMed ID: 19140379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new anti-mycobacterial agent, rifabutin].
    Kurashima A; Mori T; Tomono Y; Abe S; Nagaoka M; Abe M
    Kekkaku; 2010 Oct; 85(10):743-56. PubMed ID: 21061564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifabutin: where do we stand in 2016?
    Crabol Y; Catherinot E; Veziris N; Jullien V; Lortholary O
    J Antimicrob Chemother; 2016 Jul; 71(7):1759-71. PubMed ID: 27009031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug resistance of Mycobacterium tuberculosis is the topical problem of phthisiology].
    Samoĭlova AG; Mar'iandyshev AO
    Probl Tuberk Bolezn Legk; 2005; (7):3-9. PubMed ID: 16130417
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical management of drug-resistant tuberculosis.
    Furin J
    Curr Opin Pulm Med; 2007 May; 13(3):212-7. PubMed ID: 17414129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug resistance of Mycobacteria tuberculosis in patients with new-onset pulmonary tuberculosis].
    Khudushina TA; Voloshina EP; Adamovich NV; Maslakova MG; Terekhova ND
    Probl Tuberk Bolezn Legk; 2005; (12):37-9. PubMed ID: 16496762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 19. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
    Cavusoglu C; Karaca-Derici Y; Bilgic A
    Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance of Mycobacterium tuberculosis strains isolated from patients to antituberculosis drugs].
    Sybirna RI; Iavors'ka GV
    Mikrobiol Z; 2001; 63(4):91-5. PubMed ID: 11692684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.